Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NEKTAR THERAPEUTICS (NKTR)

Nektar reports 52-week rezpegaldesleukin data in alopecia areata and atopic dermatitis

Positive Impact 3 of 5 product/contract Written later

Nektar Therapeutics presented long-term Phase 2b data for rezpegaldesleukin at the EADV 2026 congress, including off-treatment durability in alopecia areata. The filing also says a third Phase 3 atopic dermatitis study has started and a Phase 3 alopecia areata study is planned for early 2027. The filing reports clinical data only, with no revenue, earnings, or guidance figures.

Key points

  • In alopecia areata, 75% (6 of 8) of patients maintained a SALT Score of 20 or less at 4 months off treatment, and 63% (5 of 8) at 6 months.
  • SALT Score of 10 or less responses rose from 7% at the end of week 52 to 19% after 6 months off treatment.
  • The Phase 3 ZENITH AA study in alopecia areata is planned to start in early 2027 with 850 patients.
  • Management hosted a conference call and webcast at 8:00 a.m. ET on October 1, 2026.

The filing

CompanyNEKTAR THERAPEUTICS (NKTR)
Form8-K, current report
Filed with the SECOct 1, 2026, 7:57 AM ET
Accession number0001213900-26-105453

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.